|
1
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sainsbury JR, Farndon JR, Needham GK,
Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status
as predictor of early recurrence of and death from breast cancer.
Lancet. 1:1398–1402. 1987.PubMed/NCBI
|
|
5
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balanis N, Wendt MK, Schiemann BJ, Wang Z,
Schiemann WP and Carlin CR: Epithelial to mesenchymal transition
promotes breast cancer progression via a fibronectin-dependent
STAT3 signaling pathway. J Biol Chem. 288:17954–17967. 2013.
View Article : Google Scholar
|
|
7
|
Wendt MK, Smith JA and Schiemann WP:
Transforming growth factor-beta-induced epithelial-mesenchymal
transition facilitates epidermal growth factor-dependent breast
cancer progression. Oncogene. 29:6485–6498. 2010. View Article : Google Scholar
|
|
8
|
Pankov R and Yamada KM: Fibronectin at a
glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ritzenthaler JD, Han S and Roman J:
Stimulation of lung carcinoma cell growth by fibronectin-integrin
signalling. Mol Biosyst. 4:1160–1169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fernandez-Garcia B, Eiro N, Marin L,
Gonzalez-Reyes S, Gonzalez LO, Lamelas ML and Vizoso FJ: Expression
and prognostic significance of fibronectin and matrix
metalloproteases in breast cancer metastasis. Histopathology.
512–522. 2013.PubMed/NCBI
|
|
11
|
Bae YK, Kim A, Kim MK, Choi JE, Kang SH
and Lee SJ: Fibronectin expression in carcinoma cells correlates
with tumor aggressiveness and poor clinical outcome in patients
with invasive breast cancer. Hum Pathol. 44:2028–2037. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rintoul RC and Sethi T: Extracellular
matrix regulation of drug resistance in small-cell lung cancer.
Clin Sci. 102:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma G, Singh RP, Chan DC and Agarwal R:
Silibinin induces growth inhibition and apoptotic cell death in
human lung carcinoma cells. Anticancer Res. 23:2649–2655.
2003.PubMed/NCBI
|
|
14
|
Kim S, Choi JH, Lim HI, Lee SK, Kim WW,
Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE: Silibinin
prevents TPA-induced MMP-9 expression and VEGF secretion by
inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast
cancer cells. Phytomedicine. 16:573–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim S, Kim SH, Hur SM, Lee SK, Kim WW, Kim
JS, Kim JH, Choe JH, Nam SJ, Lee JE and Yang JH: Silibinin prevents
TPA-induced MMP-9 expression by downregulation of COX-2 in human
breast cancer cells. J Ethnopharmacol. 126:252–257. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim S, Han J, Kim JS, Kim JH, Choe JH,
Yang JH, Nam SJ and Lee JE: Silibinin suppresses EGFR
ligand-induced CD44 expression through inhibition of EGFR activity
in breast cancer cells. Anticancer Res. 31:3767–3773.
2011.PubMed/NCBI
|
|
17
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferraro DA, Gaborit N, Maron R,
Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit
N, Sela M and Yarden Y: Inhibition of triple-negative breast cancer
models by combinations of antibodies to EGFR. Proc Natl Acad Sci
USA. 110:1815–1820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi J, Jung WH and Koo JS:
Clinicopathologic features of molecular subtypes of triple negative
breast cancer based on immunohistochemical markers. Histol
Histopathol. 27:1481–1493. 2012.PubMed/NCBI
|
|
20
|
Gumuskaya B, Alper M, Hucumenoglu S,
Altundag K, Uner A and Guler G: EGFR expression and gene copy
number in triple-negative breast carcinoma. Cancer Genet Cytogenet.
203:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martin V, Botta F, Zanellato E, Molinari
F, Crippa S, Mazzucchelli L and Frattini M: Molecular
characterization of EGFR and EGFR-downstream pathways in triple
negative breast carcinomas with basal like features. Histol and
Histopathol. 27:785–792. 2012.PubMed/NCBI
|
|
23
|
Liu D, He J, Yuan Z, Wang S, Peng R, Shi
Y, Teng X and Qin T: EGFR expression correlates with decreased
disease-free survival in triple-negative breast cancer: a
retrospective analysis based on a tissue microarray. Med Oncol.
29:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ackland ML, Newgreen DF, Fridman M,
Waltham MC, Arvanitis A, Minichiello J, Price JT and Thompson EW:
Epidermal growth factor-induced epithelio-mesenchymal transition in
human breast carcinoma cells. Lab Invest. 83:435–448. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun X, Fa P, Cui Z, Xia Y, Sun L, Li Z,
Tang A, Gui Y and Cai Z: The EDA-containing cellular fibronectin
induces epithelial-mesenchymal transition in lung cancer cells
through integrin α9β1-mediated activation of PI3-K/AKT and Erk1/2.
Carcinogenesis. 35:184–191. 2014.PubMed/NCBI
|
|
26
|
Sudo T, Iwaya T, Nishida N, Sawada G,
Takahashi Y, Ishibashi M, Shibata K, Fujita H, Shirouzu K, Mori M
and Mimori K: Expression of mesenchymal markers vimentin and
fibronectin: the clinical significance in esophageal squamous cell
carcinoma. Ann Surg Oncol. 20:S324–S335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Choi JH, Lim HI, Lee SK, Kim WW,
Cho S, Kim JS, Kim JH, Choe JH, Nam SJ, Lee JE and Yang JH:
EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway,
but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell
line. Cell Signal. 21:892–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim S, Han J, Lee SK, Koo M, Cho DH, Bae
SY, Choi MY, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE:
Smad7 acts as a negative regulator of the epidermal growth factor
(EGF) signaling pathway in breast cancer cells. Cancer Lett.
314:147–154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayashida T, Poncelet AC, Hubchak SC and
Schnaper HW: TGF-beta1 activates MAP kinase in human mesangial
cells: a possible role in collagen expression. Kidney Int.
56:1710–1720. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uchiyama-Tanaka Y, Matsubara H, Mori Y,
Kosaki A, Kishimoto N, Amano K, Higashiyama S and Iwasaka T:
Involvement of HB-EGF and EGF receptor transactivation in
TGF-beta-mediated fibronectin expression in mesangial cells. Kidney
Int. 62:799–808. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Helleman J, Jansen MP, Ruigrok-Ritstier K,
van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn
JG, Sleijfer S, Foekens JA and Berns EM: Association of an
extracellular matrix gene cluster with breast cancer prognosis and
endocrine therapy response. Clin Cancer Res. 14:5555–5564. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao ES, Zhang H, Chen YY, Lee B, Chew K,
Moore D and Park C: Increased beta1 integrin is associated with
decreased survival in invasive breast cancer. Cancer Res.
67:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vergara D, Valente CM, Tinelli A,
Siciliano C, Lorusso V, Acierno R, Giovinazzo G, Santino A,
Storelli C and Maffia M: Resveratrol inhibits the epidermal growth
factor-induced epithelial mesenchymal transition in MCF-7 cells.
Cancer Lett. 310:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grande M, Franzen A, Karlsson JO, Ericson
LE, Heldin NE and Nilsson M: Transforming growth factor-beta and
epidermal growth factor synergistically stimulate epithelial to
mesenchymal transition (EMT) through a MEK-dependent mechanism in
primary cultured pig thyrocytes. J Cell Sci. 115:4227–4236. 2002.
View Article : Google Scholar
|
|
35
|
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei
Y, Abbruzzese JL, Hortobagyi GN and Hung MC: Epidermal growth
factor receptor cooperates with signal transducer and activator of
transcription 3 to induce epithelial-mesenchymal transition in
cancer cells via upregulation of TWIST gene expression. Cancer Res.
67:9066–9076. 2007. View Article : Google Scholar
|
|
36
|
Kasai H, Allen JT, Mason RM, Kamimura T
and Zhang Z: TGF-beta1 induces human alveolar epithelial to
mesenchymal cell transition (EMT). Respir Res. 6:562005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheung CW, Gibbons N, Johnson DW and Nicol
DL: Silibinin - a promising new treatment for cancer. Anticancer
Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
